Clinical Trials Browser

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Phase 1/2 Completed

341 enrolled 28 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT02060188 2025-11-06

CheckMate142

Phase 2 Completed

385 enrolled 17 charts 2 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT03600701 2025-10-07

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Phase 2 Active not recruiting

51 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04079179 2025-09-18

NACHO-COBI

Phase 2 Recruiting

90 enrolled

MyeloidSarcoma

Histiocytosis, Langerhans-Cell, Xanthogranuloma, Juvenile, Histiocytosis, Sinus, Histiocytic Disorders, Malignant, Erdheim-Chester Disease, Histiocytic Sarcoma

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

300 enrolled

Tumor-Agnostic

Neoplasms

NCT02908672 2025-07-20

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Phase 3 Completed

514 enrolled 25 charts 1 FDA

Dermatologic

Melanoma

Clinical Trials

B-FAST

TAPUR

NAUTIKA1

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Morpheus Lung

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

IMbrella B

CONCERTO

COTESARC

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

CAPTUR

BOUQUET

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

DETERMINE